This study explored the prevalence and related risk behaviors for hepatitis C (HCV), hepatitis B (HBV), and human immunodeficiency virus (HIV) among a sample of male injection drug users (IDUs) in Arak, Iran. One hundred male IDUs attending methadone maintenance clinics between April and September 2012 were enrolled and evaluated for HCV, HBV, and HIV infection. The majority of study participants (56%) had evidence of HCV exposure, 6% had evidence of HBV, and 19% were HIV-infected. Coinfections were frequent; 15% had evidence of HIV and HCV, 6% had evidence of HBV and HCV, and 5% had serologic markers for all three infections. Most (84%) were susceptible to HBV infection. A history of any syringe sharing (54%) and syringe sharing in prison (25%) were common. In bivariate analyses, a history of any syringe sharing and syringe sharing in prison were both associated with all three viral infections. The high prevalence of HCV, HBV, HIV, and coinfections among IDU in Arak is concerning and indicates rapid disease spread outside of Iran's main urban centers. Prevention efforts should expand vaccination for IDUs who are nonimmune to HBV and continue to target syringe sharing with efforts such as needle exchange programs, including inside prisons.
Introduction
Injection drug users (IDUs) are at increased risk for acquiring blood-borne viruses including hepatitis C (HCV), hepatitis B (HBV), and human immunodeficiency virus (HIV) through unsafe drug injection (Degenhardt & Hall, 2012; Mathers et al., 2008; Mir-Nasseri, Mohammadkhani, Tavakkoli, Ansari, & Poustchi, 2011; Nelson et al., 2011) . In Iran, the HIV epidemic is concentrated among IDUs, with as many as 70% of all HIV infections attributed to unsafe injection drug use (MoH, 2011) . Notably, a recent study of IDU in Tehran, by far the nation's largest city, showed an HCV, HIV, and HBV prevalence of 70%, 16%, and 4%, respectively (Mir-Nasseri et al., 2011) . Other estimates of HCV infection among IDUs in other urban areas of Iran have ranged from 59 to 90% (Kheirandish et al., 2009; Mohtasham Amiri, Rezvani, Jafari Shakib, & Jafari Shakib, 2007; Rowhani-Rahbar, Rooholamini, & Khoshnood, 2004) .
Less information is available on the epidemiology of these infections and related behaviors among IDUs outside of Iran's principal urban centers. This study aimed to determine the prevalence of HCV, HBV, and HIV infection among IDUs in Arak, a moderate sized city in a central province (Markazi) of Iran. As all three of these infections are preventable, we also sought to better characterize the behaviors that have been associated with these infections in order to guide the ongoing development and implementation of appropriate preventive strategies for this at-risk population.
Methods
We enrolled a total of 100 IDUs attending methadone maintenance clinics in Arak, Iran, between April and September 2012. This site was selected because it is outside Iran's major population centers, has a wellestablished substance abuse clinic, and is affiliated with a research university. IDUs were eligible for participation if they reported a history of injecting drugs in the preceding three months and were willing and able to provide informed consent. In Iran, individuals aged 15 or older have reached the legal age of consent for research based on the national ethical codes. The study protocol was approved by the ethical review committee at Arak University of Medical Sciences. No incentives were given.
After informed consent, participants completed a questionnaire during a face-to-face interview conducted by a trained physician. The questionnaire assessed demographic characteristics and related risk behaviors for HCV, HBV, and HIV transmission. Participants were tested for HCV antibody (anti-HCV), HBV surface antigen (HBsAg), surface antibody (anti-HBs), and core antibody (anti-HBc) using enzyme-linked immunosorbent assays (ELISAs) by Enzygnost (Dade Behring, Marburg GmbH, Germany). HIV infection was diagnosed by ELISA (MP Biomedicals, Illkirch, France) with confirmatory Western blot (Diaplus, San Francisco, USA). For the purpose of our analyses, all participants with anti-HCV were considered collectively as having been exposed; we did not distinguish between chronic HCV infection and those with prior HCV exposure who had cleared the virus. Participants who were positive for HBsAg were classified as HBV-infected; participants who were negative for HBsAg, anti-HBs, and anti-HBc were classified as nonimmune. All IDUs who were susceptible to HBV were referred for vaccination; HIVinfected individuals were referred to free clinics if not already in care.
Associations between HCV, HBV, and HIV infections and related risk factors were assessed in bivariate analyses using the Chi-square or the Mann-Whitney U tests. Statistical analyses were performed using SPSS, version 16 (SPSS, 2007) .
Results
Baseline demographic and risk behavior characteristics of the 100 men enrolled are described in Table 1 , with the participants further stratified by HCV, HBV, and HIV infection. The participants ranged in age from 17 to 58 (median 33.3 years). Heroin (93%) and "crack" or "kerack" (49%)a local, highly potent opioid injectable drugwere the most commonly injected drugs; a substantial majority (59%) reported a history of smoking opium. "Kerack" use was especially common among those with HIV (79%). A history of incarceration (73%), any syringe sharing (54%), and syringe sharing in prison (25%) were common. Among those with HCV, HBV, and HIV, a history of incarceration (82, 100, and 89%, respectively), any syringe sharing (75, 100, 89%, respectively), and syringe sharing in prison (38, 83, and 68%, respectively) were frequently reported.
In our sample, 56% of the IDUs were anti-HCV positive, while 6% had evidence of HBV infection (HBsAg-positive) and 19% were HIV-infected. Viral coinfections were common in our sample, with HIV/ HCV at 15%, followed by HCV/HBV at 6%, and HIV/ HCV/HBV at 5%. Only 10% were anti-HBs positive. The majority (84%) of the IDUs were both anti-HBs-and anti-HBc-negative, and therefore, potentially susceptible to HBV infection and candidates for vaccination.
In bivariate analyses, a history of sharing syringes was associated with HCV (odds ratio [OR]: 9.77, 95% confidence interval [CI]: 3.90-24.49), HBV (OR: 9.38, 95% CI: 0.94-93.27), and HIV (OR: 9.70, 95% CI: 3.90-24.40). Furthermore, a history of sharing syringes specifically in prison was also associated with HCV (OR: 6.17, 95% CI: 1.93-19.60), HBV (OR 17.85, 95% CI 1.98-166.66), and HIV (OR: 14.92, 95% CI; 4.50-49.62). IDUs who reported sharing containers for storing injection equipment were more likely to be HCV-exposed (OR: 3.67, 95% CI: 1.60-8.42). Infection with HCV, HBV, or HIV was associated with coinfection with the other two viruses in bivariate analyses (HCV and HBV, OR: 1.89, 95% CI: 1.56-2.30; HCV and HIV, OR: 3.65, 95% CI: 1.11-11.97; and HBV and HIV, OR: 28.21, 95% CI: 3.06-260.03). In addition, participants who reported longer durations of imprisonment (OR: 1.01 per month, 95% CI: 1.00-1.03), "kerack" use (OR: 5.18, 95% CI: 1.58-17.01), and dental procedures (OR: 3.50, 95% CI: 1.15-10.63) were more likely to be HIV-infected.
Discussion
In this study of male IDUs in Arak, an urban area in central Iran, we found very high prevalence of HCV exposure (56%), hepatitis B (6%), and HIV infection (19%). A history of syringe sharing and syringe sharing specifically in prison were commonly reported, and these risk behaviors were associated with all three viral infections in bivariate analyses. Our results are consistent with several prior studies that found sharing blood-contaminated injection equipment to be the most important risk factor associated with HCV infection (Alter & Moyer, 1998; Alter et al., 1999; Samuel, Doherty, Bulterys, & Jenison, 2001; Stark, Bienzle, Vonk, & Guggenmoos-Holzmann, 1997) . These findings emphasize the need to expand the availability of clean needles through needle exchange programs, including inside Iranian prisons, to minimize ongoing disease transmission.
Also consistent with prior studies, we found that infection with each of these three blood-borne viruses significantly increased the probability of being exposed to the other two viruses (Xia, Luo, Bai, & Yu, 2008) , a finding that reflects their shared underlying transmission routes. Given that 84% in our study were HBV nonimmune, many IDUs in Iran may acquire HBV sexually or through blood transmission rather than through vertical transmission. Adult vaccination for HBV nonimmune IDUs will be beneficial for this very high-risk population.
In Iran, previously identified risk factors for HCV include frequency and duration of injection use, AIDS Care 1123 initiation of drug use at a young age, sharing needles in prison, a history of incarceration, certain sexual practices, and a history of tattooing (Amin-Esmaeli, Rahimi-Movaghar, Razaghi, Baghestani, & Jafari, 2012; Kassaian et al., 2012; Kheirandish et al., 2009; Sofian et al., 2012; Skoretz, Zaniewski, & Goedhuis, 2004) . Duration of drug use and a history of incarceration have also been associated with HBV infection (Amin-Esmaeli et al., 2012) . In our analyses, we found very high prevalence of "kerack" use among participants with HIV. Prior research suggests that differing syringe and equipment-sharing patterns between various drugs may explain this finding (Mahanta, Borkakoty, Das, & Chelleng, 2009 ). The primary limitation of our study is the small sample size, especially for IDU with HIV or HBV. A second limitation of our study is that we only included participants attending methadone maintenance clinics, and these IDUs may not be representative of IDUs in Arak more generally. Third, although we made an effort to elicit all behavioral data nonjudgmentally and confidentially, social desirability bias and fear of lack of confidentiality may have lead to an underreporting of certain risk behaviors. In addition, HCV infection clears without treatment in 15-40% of those exposed (Rockstroh & Spengler, 2004) , and consequently, our study may overestimate the percentage of IDU at risk for HCVrelated chronic liver disease. Finally, we did not collect data on frequency and duration for risk behaviors such as syringe sharing, and these data may have offered a more nuanced understanding of these risk behaviors.
Nonetheless, our data clearly document an alarming prevalence of HCV, HBV, and HIV, as well as coinfections among IDUs in Arak. The large number of men who reported unsafe injection practices in this study highlights an ongoing risk for HCV, HBV, and HIV transmission and emphasizes the need for expansion of public health interventions for this at-risk population. In order to reduce future morbidity and mortality from HCV, HBV, and HIV infection, harm reduction interventions for IDU in secondary urban centers and more rural areas should remain a public health priority in Iran, and these interventions must address the practice of syringe sharing both inside and outside of prison. 
